Boosting bioprospects

Article Abstract:

Drug companies have stopped funding bioprospectsing enterprises, a short-sighted business strategy, as a result of which few economic rewards are returning to developing nations. A new framework for access and benefit sharing is developed and a key component of this framework is a certificate of origin that links compounds discovered in the jungle to drugs that may be developed at pharmaceutical companies.

Financial management, Usage, Economic aspects, Finance, Company financing

---

Addicted to secrecy

Article Abstract:

Scientific bodies want most of the public-health data to be released into the public domain. The industry's reputation may benefit in the long run from arrangements that get information about drug safety into the public domain and might ensure that companies are fully complying global secrecy registers.

United States, Legal issues & crime, Government regulation (cont), General services, Government regulation, Health Care and Social Assistance, HEALTH SERVICES, Public Health Care, Legal/Government Regulation, Administration of Public Health Programs, Health Programs-Total Govt, Administration of Human Resource Programs, Health Programs, Safety and security measures, Laws, regulations and rules, Public health, Secrecy

---

Similar abstracts:

• Abstracts: Boosting biotech in Finland. Debate, what debate?
• Abstracts: Biologists launch 'open-source movement'. Synthetic sex cells. Parasite vaccines: Sweet revenge
• Abstracts: Barkley accused of biotech bias as ecologist is denied tenure. Biotech funding deal judged to be 'a mistake' for Berkeley
• Abstracts: Scratching the surface. Stored in the rings. True blue
• Abstracts: A new perspective on parks. The white-footed mouse ain't what it used to be. Cash for cedars and cuipos

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.